Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY) from its SEC filings: 2025 revenue $868.5 million (+22% vs the year before), net margin 18%, free cash flow $347.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $868.5 million |
| Revenue growth | +22% |
| Net income | $158.7 million |
| Net margin | 18.3% |
| Free cash flow | $347.9 million |
| Diluted EPS | $2.71 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +30% |
| Cash | $549.8 million |
| Long-term debt | $134.0 million |
| Share count, 1 year | +1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.